| 2026-08-05 | Press release | Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercia |
| 2026-07-28 | Press release | Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Ne |
| 2026-07-22 | Press release | Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failur |
| 2026-06-30 | Press release | Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as |
| 2026-06-25 | Press release | Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend |
| 2026-06-23 | Press release | Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of C |
| 2026-06-22 | Press release | Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intesti |
| 2026-06-18 | Press release | Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclini |
| 2026-06-12 | Press release | Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofe |
| 2026-06-08 | Press release | Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders |
| 2026-05-28 | Press release | Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Cong |
| 2026-05-27 | Press release | Jaguar Health Compliant with Nasdaq Bid Price Rule |
| 2026-05-19 | Press release | Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients w |
| 2026-05-08 | Press release | Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until |
| 2026-05-06 | Press release | Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for |
| 2026-05-04 | Press release | Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health |
| 2026-04-29 | Press release | Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia |
| 2026-04-27 | Press release | Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Anno |
| 2026-04-24 | Press release | Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Fai |
| 2026-04-20 | Press release | Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders |
| 2026-04-13 | Press release | Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Cr |
| 2026-04-08 | Press release | Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Dia |
| 2026-04-07 | Press release | Jaguar Health Reports 2025 Financials |
| 2026-04-02 | Press release | Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Cong |
| 2026-03-18 | Press release | FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Incl |
| 2026-03-16 | Press release | Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca fo |
| 2026-03-11 | Press release | Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts |
| 2026-03-09 | Press release | Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extingu |
| 2026-03-03 | Press release | Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 |
| 2026-03-02 | Press release | Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend |
| 2026-02-18 | Press release | Jaguar Health Announces a Special One-time Stock Dividend |
| 2026-01-22 | Press release | Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Clo |
| 2026-01-14 | Press release | Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Cataly |
| 2026-01-12 | Press release | Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million |
| 2026-01-06 | Press release | Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featur |
| 2026-01-02 | Press release | Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID |
| 2023-10-18 | Press release | https://jaguar.health/wp-content/uploads/2023/10/Mergermarket-10.18.23.pdf |